A slide from a presentation. It appears to be a slide showing one step in how to convert a sample patient to Exalgo. The Exalgo logo is in the upper-right corner. The title of the slide is "Case 2: Jennifer: EXALGO Conversion Initiation and Titration." The title has a blue background with white text. On the left side of the slide there is a photo of Jennifer a woman with long brown hair and a serious expression on her face. She is wearing a gray blazer and is standing in front of a white background.
On the left side there is a heading followed by two bullet points. The heading reads "Calculate the Estimated Equianalgesic Dose" It has two bullet points reading: "Sum the total daily opioid therapy" and then "Multiply by the conversion ratio". There is a table showing Exalgo conversion ratios and the section most relevant to Jennifer's dosage is highlighted as an inset.
Description
Type 
Category
Source 1 of 4
-
Date
2012
Collection
-
Date
2012
Collection
-
Date
2012
Collection
-
Date
2012
Collection
We encourage you to view the image in the context of its source document(s) and cite the source(s) when using these images. However, to cite just this image alone, click the “Cite This Image” button and then paste the copied text.
![Information about NUCYNTA ER. It is titled "NUCYNTA ER: better GI tolerability than oxycodone CR in a 1-year safety study". There is a bar graph at the center of the image titled "Incidence of the treatment-emergent adverse events reported [...] treatment group in a 52-week study (osteoarthritis[...]". The x-axis values between 0 and 40. The y-axis has a number of adverse events. The graph shows that NUCYNTA ER had a lower incidence of adverse events than Oxycodone for nausea vomiting constipation dizziness and skin pruritus (itching). It shows that Oxycodone had a lower incidence of adverse events for diarrhea dry mouth somnolence and headache. They show equal values for fatigue. The bars for nausea vomiting and constipation are at the top of the graph and they are highlighted in brighter colors. An arrow points to these bars and is labeled "50% lower incidence of nausea vomiting and constipation vs. oxycodone CR". <br /><br />The image also shows a red side bar with the NUCYNTA ER logo and selected important safety information.](https://oida-resources-images.azureedge.net/public/full/bdae85ed-5038-4ac0-8738-b5232296aa03.jpg)